0001144204-17-010171.txt : 20170221 0001144204-17-010171.hdr.sgml : 20170221 20170221162908 ACCESSION NUMBER: 0001144204-17-010171 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170221 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170221 DATE AS OF CHANGE: 20170221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-PATH HOLDINGS INC CENTRAL INDEX KEY: 0001133818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870652870 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36333 FILM NUMBER: 17625412 BUSINESS ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 BUSINESS PHONE: (832) 742-1357 MAIL ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 FORMER COMPANY: FORMER CONFORMED NAME: OGDEN GOLF CO CORP DATE OF NAME CHANGE: 20010205 8-K 1 v460118_8k.htm FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of report (Date of earliest event reported): February 21, 2017

 

BIO-PATH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware 001-36333 87-0652870

(State or other jurisdiction

of incorporation)

 

 (Commission File Number) (IRS Employer Identification No.)

 

4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401
(Address of principal executive offices) (Zip Code)

 

(832) 742-1357

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On February 21, 2017, Bio-Path Holdings, Inc. (the “Company”) issued a press release announcing the appointment of D. Craig Hooper, Ph.D. to the Company’s Scientific Advisory Board. A copy of such press release, which includes certain biographical information of Dr. Hooper, is attached hereto as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit

NumberDescription

 

99.1Press Release dated February 21, 2017

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  BIO-PATH HOLDINGS, Inc.
   
Dated: February 21, 2017 By:  /s/ Peter H. Nielsen
         Peter H. Nielsen
     President and Chief Executive Officer

 

 

 

 

 

EXHIBIT INDEX

 

 

Exhibit

NumberDescription

 

99.1Press Release dated February 21, 2017

 

 

 

 EX-99.1 2 v460118_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Creative2448_2

 

 

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

 

Renowned neuroimmunology researcher joins SAB to advance DNAbilize™ technology in glioblastoma

 

HOUSTON—February 21, 2017 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of D. Craig Hooper, Ph.D., to its Scientific Advisory Board (SAB).

 

“It is with great pleasure we welcome Dr. Hooper to our SAB. His extensive experience in the neuroimmunology field will be extremely valuable to Bio-Path as we seek to advance our liposomal RNAi antisense platform to deliver a safe and systemic brain cancer immunotherapy,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.

 

“Bio-Path is developing a truly innovative platform that has the potential to transform antisense drug delivery,” commented Dr. Hooper. “I’m honored to join Bio-Path’s SAB and look forward to working with my esteemed colleagues to help advance DNAbilize™ and offer meaningful new immunotherapy treatments to patients.”

 

D. Craig Hooper, Ph.D., is a Professor of Cancer Biology and Neurological Surgery at Thomas Jefferson University. Dr. Hooper has published over 140 papers in peer-reviewed journals and serves on the editorial boards of the Journal of Immunology Research, Scientific Reports and the Journal of Immunology. In 2016 he was inducted into the National Academy of Inventors (NAI). Dr. Hooper received his Ph.D. in Immunology and B.Sc. in Physiology from McGill University. He completed his post-doctoral research fellowship at the University of Bristol.

 

About Bio-Path Holdings, Inc.

 

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

 

For more information, please visit the Company's website at http://www.biopathholdings.com.

 

 

# # #

 

 

Contact Information:

 

Investors

 

Will O’Connor

Stern Investor Relations, Inc.

212-362-1200

will@sternir.com

 

Doug Morris

Investor Relations

Bio-Path Holdings, Inc.

832-742-1369

 


 

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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